Knowledge-Based Firm Unveils New Medicine for Cutaneous Leishmaniasis
An Iranian technological company unveiled its knowledge-based drug Leish G1 at the INOTEX 2023 exhibition in the presence of media, including ANA News Agency.
Payandeh, the managing director of "Behpad Teb Iranian" technological company located at Pardis Technology Park said, "Our products are result of three decades of research focusing on producing drugs and supplements that strengthen and regulate human immune system to treat illnesses such as cancer, infectious and inflammatory diseases, etc."
He pointed to the three important objectives that their technologal company pursues, saying, "Production of drugs that regulate the immune system, technical know-how in the field of production, exploring, discovering, identification and extraction of effective materials, and finally the production of supplements that regulate the immune system are among the missions we have focused on."
Ashrafi, a pharmacist and one of the managers of the knowledge-based company, for his part, said, "There will be many diseases when the body's immune system will go out of its normal order. Therefore, the specialists of our company try to detect and extract natural effective substances from indigenous plants in the country that can regulate the body's immune system."
"Our product is a type of topical ointment that has been produced with the 30-year technical knowledge of the company's specialists. This product has a germicidal impact topically on the wound and can strengthen the immune system," he went on to say.
"Currently, the medicine available for this disease is the injection of glucantin in the wound site, which is very painful and annoying for the patient. But leish G1 medicinal product has a strengthening effect on the immune system in addition to the germicidal effect on the wound site and heals the wound scar."
"The product will be available to patients in about a month, and according to the technical manager of the company, 88 countries in the world have reported this disease, so entering the internationl market is one of the objectives," he added.
Leish G1 drug is the result of numerous cell, animal and human studies, which is used with new formulation and effective internal ingredients to heal the wound of cutaneous leishmaniasis, the researcher added.
The capablity of strengthening the immune system, the capability to heal the wound, being anti-parasitic, the absence of systemic side effects are some of the properties that make the drug superior over others, the manager added.
INOTEX is Iran’s biggest innovation and technology event, which is held annually to bring together high-tech companies, startups, accelerators as well as venture capital funds in order to share experience and bring viable ideas to the market.
4155/i
